Literature DB >> 32402304

Management of Rectal Cancer.

Neal Wilkinson1.   

Abstract

Rectal cancer is often presented with a dizzying array of treatment recommendations. This article clarifies and simplifies this common clinical problem from the surgical perspective. Treatment of rectal cancer requires an understanding of presenting stage (early or advanced) and location (high or low) to provide oncologic sound treatment decisions. Surgical treatment requires a minimum of 1 cm distal margin, careful clearance of the mesorectum and radial margin using total mesorectal excision technique, and 12 or more regional lymph nodes harvested and analyzed. Appropriate and effective multimodality treatments exist and must be used based on sound guidelines as outlined.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Multimodality treatment; Rectal cancer; Staging; Surgical techniques

Mesh:

Year:  2020        PMID: 32402304     DOI: 10.1016/j.suc.2020.02.014

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  10 in total

1.  Temporary vs. permanent stoma: factors associated with the development of complications and costs for rectal cancer patients.

Authors:  Iktej S Jabbal; Aaron C Spaulding; Riccardo Lemini; Shalmali R Borkar; Krystof Stanek; Dorin T Colibaseanu
Journal:  Int J Colorectal Dis       Date:  2022-02-24       Impact factor: 2.571

2.  Bowel seromuscular flaps used to repair pelvic defects in patients undergoing reoperative surgery.

Authors:  J S Bauzon; N V Tran; B R Hebert; K L Mathis
Journal:  Tech Coloproctol       Date:  2022-09-06       Impact factor: 3.699

3.  Prognostic and clinical significance of subcellular CDC27 for patients with rectal adenocarcinoma treated with adjuvant chemotherapy.

Authors:  Chia-Lin Chang; Kevin Chih-Yang Huang; Tsung-Wei Chen; William Tzu-Liang Chen; Hsuan-Hua Huang; Ya-Ling Liu; Chia-Hui Kuo; K S Clifford Chao; Tao-Wei Ke; Shu-Fen Chiang
Journal:  Oncol Lett       Date:  2022-05-31       Impact factor: 3.111

4.  Application of Transurethral Prostate Resection Instrumentation for Treating Low Rectal Anastomotic Leakage: A Pilot Study.

Authors:  Zhenming Zhang; Zhentao Hu; Yujie Qin; Jun Qian; Song Tu; Jiaxi Yao
Journal:  Cancer Manag Res       Date:  2022-06-16       Impact factor: 3.602

5.  Analysis of Prognostic Factors of Rectal Cancer and Construction of a Prognostic Prediction Model Based on Bayesian Network.

Authors:  Ruikai Li; Chi Zhang; Kunli Du; Hanjun Dan; Ruxin Ding; Zhiqiang Cai; Lili Duan; Zhenyu Xie; Gaozan Zheng; Hongze Wu; Guangming Ren; Xinyu Dou; Fan Feng; Jianyong Zheng
Journal:  Front Public Health       Date:  2022-06-17

6.  Apoptosis-Associated Gene Expression Profiling Is One New Prognosis Risk Predictor of Human Rectal Cancer.

Authors:  Qiansan Zhu; Xian Wu; Lili Ma; Haibo Xue
Journal:  Dis Markers       Date:  2022-04-23       Impact factor: 3.464

7.  Efficacy and safety of intraoperative radiotherapy in rectal cancer: A systematic review and meta-analysis.

Authors:  Bin Liu; Long Ge; Jing Wang; Ya-Qiong Chen; Shi-Xun Ma; Pei-Lan Ma; Yun-Qiang Zhang; Ke-Hu Yang; Hui Cai
Journal:  World J Gastrointest Oncol       Date:  2021-01-15

Review 8.  Minimally Invasive Endoscopic and Surgical Management of Rectal Neoplasia.

Authors:  Sarah S Al Ghamdi; Ira Leeds; Sandy Fang; Saowanee Ngamruengphong
Journal:  Cancers (Basel)       Date:  2022-02-14       Impact factor: 6.639

9.  Submucosal resection via a transanal approach for treatment of epithelial rectal tumors - a multicenter study.

Authors:  Matteo Cantatore; Juan Carlos Jimeno Sandoval; Smita Das; Alberto Sesana; Tim Charlesworth; Tony Ryan; Emanuela M Morello; Matteo Gobbetti; Filippo Cinti; Matteo Rossanese
Journal:  Vet Surg       Date:  2022-01-08       Impact factor: 1.618

10.  Amide Proton Transfer Weighted and Intravoxel Incoherent Motion Imaging in Evaluation of Prognostic Factors for Rectal Adenocarcinoma.

Authors:  Juan Li; Liangjie Lin; Xuemei Gao; Shenglei Li; Jingliang Cheng
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.